Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

19384 items
12:00 AM, Jul 26, 1993  |  BioCentury | Strategy

Lilly explains accelerated development goals

Lilly explains accelerated development goals The changes being contemplated by Eli Lilly and Co.'s management, if the company can pull them off, should be a plus for Lilly's current and future biotech partners. The company...
12:00 AM, Jul 26, 1993  |  BioCentury | Strategy

Gensia votes for its sales force

Gensia votes for its sales force Marketing decisions can depend on what indications a company chooses to develop first. One indication may make it wise to co-market, while another may enable a company to retain...
12:00 AM, Jul 26, 1993  |  BioCentury | Product Development

The thinking behind Lidakol trials

The thinking behind Lidakol trials Like many biotech company executives who now realize that getting most products through the FDA won't be a slam dunk, Lidak Pharmaceuticals Inc. chairman and CEO David Katz has been...
12:00 AM, Jul 26, 1993  |  BioCentury | Product Development

Idec pulls the plug on Specifid

Poised to begin Phase II and III studies of its Specifid panel of 15 antibodies for B-cell lymphoma, Idec Pharmaceuticals Corp. instead has decided to drop Specifid in favor of its single-antibody pan-B products. The...
12:00 AM, Jul 26, 1993  |  BioCentury | Strategy

Cytel trims R&D projects, jobs

Cytel trims R&D projects, jobs Cytel Corp. told BioCentury that it has decided to scale back certain long-term research efforts in order to focus on its two priority projects: cell adhesion and antigen recognition. As a...
12:00 AM, Jul 26, 1993  |  BioCentury | Regulation

Worries about patent scrutiny

WASHINGTON - The U.S. Patent and Trademark Office is rejecting numerous biotechnology patent applications that fail to prove utility with data from animal or human trials, according to members of the American Intellectual Property Law...
12:00 AM, Jul 26, 1993  |  BioCentury | Strategy

AZT dispute isn't over

AZT dispute isn't over WASHINGTON - A federal court judge's summary judgement in favor of Burroughs Wellcome's exclusive patent rights to AZT has set the stage for an appellate court to rule on a basic...
12:00 AM, Jul 26, 1993  |  BioCentury | Finance

Cleaning out

Cleaning out Vical's successful public offering, coupled to Chiron's Betaseron approval last week, may have heightened some optimism for stocks as the summer winds into August and toward Labor Day. But we're still watching with...
12:00 AM, Jul 19, 1993  |  BioCentury | Strategy

Activase sales

Activase sales GNE's growing product story Estimated Activase sales, in millions of dollars each month. The GUSTO trial results were announced April 30. Source: Vector Securities International...
12:00 AM, Jul 19, 1993  |  BioCentury | Strategy

ImmunoGen rescues its product

ImmunoGen rescues its product ImmunoGen Inc. (IMGN), which has dropped Roussel-Uclaf as its European development and marketing partner for Oncolysin B, hopes to conclude a new partnership within nine to 18...

Pages